<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00582985</url>
  </required_header>
  <id_info>
    <org_study_id>105ST101</org_study_id>
    <nct_id>NCT00582985</nct_id>
  </id_info>
  <brief_title>Open Label Phase 1 Dose Finding Study of TRC105 in Patients With Solid Cancer</brief_title>
  <official_title>An Open Label Phase 1 Dose Finding Study of TRC105 in Patients With Advanced or Metastatic Solid Cancer for Whom Curative Therapy is Unavailable</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tracon Pharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tracon Pharmaceuticals Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being performed to evaluate the safety and tolerability of the TRC105
      monoclonal antibody.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In addition to safety, this study will also evaluate pharmacokinetics, tumor response and
      anti-TRC105 antibody formation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability will be evaluated</measure>
    <time_frame>Through last patient last visit</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose Limiting Toxicities</measure>
    <time_frame>28 day evaluation period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of TRC105 monoclonal antibody</measure>
    <time_frame>through last patient last visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of responses by tumor type</measure>
    <time_frame>through last patient last visit</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">51</enrollment>
  <condition>Cancer</condition>
  <condition>Neoplasm Metastasis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TRC105 chimeric anti-CD105 antibody</intervention_name>
    <description>TRC105 is a human/murine chimeric IgG1 antibody administered i.v. every two weeks (on days 1 and 15) or weekly (on days 1, 8, 15 and 22) of each 28 day cycle; until progression or unacceptable toxicity develops.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient has given informed consent.

          -  The patient is willing and able to abide by the protocol.

          -  The patient has cancer and curative therapy is unavailable.

          -  The patient is at least 18 years old.

          -  The patient has adequate ability to perform activities of daily living.

          -  Significant toxicities from prior therapy must have recovered.

          -  The patient has adequate organ function as assessed by laboratory test.

        Exclusion Criteria:

          -  The patient weighs more than 264 lbs.

          -  The patient has a known allergy to gentamicin

          -  The patient has had prior treatment with high-dose chemotherapy requiring stem cell
             rescue

          -  The patient is currently on treatment on another therapeutic clinical trial or has
             received an investigational agent within 4 weeks prior to first dose with study drug

          -  The patient has had prior surgery (including open biopsy), radiation therapy or
             systemic therapy within 4 weeks of starting the study treatment

          -  The patient has hypertension &gt; 160/90

          -  The patient has a history of CNS cancer

          -  The patient has an unstable medical condition including, but not limited to, cardiac
             disease, history of stroke, active hepatitis, or significant pericardial, pleural or
             peritoneal effusion

          -  The patient received recent thrombolytic or anticoagulant therapy

          -  The patient has lung cancer with central chest lesions

          -  The patient has had hemorrhage or unhealed wounds within 30 days of dosing

          -  The patient has used systemic corticosteroids within 3 months of dosing

          -  The patient has known HIV/AIDS

          -  The patient has a history of hypersensitivity reaction to human or mouse antibody
             products

          -  The patient is pregnant or breastfeeding.

          -  The patient has a history of peptic ulcer disease or gastritis within 6 months of
             dosing, unless complete resolution has been documented by esophagogastroduodenoscopy
             (EGD) within 30 days of dosing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bryan R Leigh, MD</last_name>
    <role>Study Director</role>
    <affiliation>Tracon Pharmaceuticals Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 19, 2007</study_first_submitted>
  <study_first_submitted_qc>December 19, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 28, 2007</study_first_posted>
  <last_update_submitted>March 2, 2012</last_update_submitted>
  <last_update_submitted_qc>March 2, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 5, 2012</last_update_posted>
  <responsible_party>
    <name_title>Bryan Leigh, MD, Medical Monitor</name_title>
    <organization>TRACON Pharmaceuticals, Inc.</organization>
  </responsible_party>
  <keyword>Tracon</keyword>
  <keyword>CD105</keyword>
  <keyword>Anti CD105</keyword>
  <keyword>TRC105</keyword>
  <keyword>Phase 1</keyword>
  <keyword>Cancer</keyword>
  <keyword>Monoclonal antibody</keyword>
  <keyword>Solid Tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

